Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2013 May 21;80(21):1934-41. doi: 10.1212/WNL.0b013e318293e1a1. Epub 2013 Apr 24.

8OHdG is not a biomarker for Huntington disease state or progression.

Author information

1
CHDI Management/CHDI Foundation, Princeton, NJ, USA. beth.borowsky@chdifoundation.org

Abstract

OBJECTIVE:

To evaluate plasma 8-hydroxy-deoxy-guanosine (8OHdG) levels as a potential biomarker of premanifest and early Huntington disease (HD).

METHODS:

Personnel from 2 independent laboratories quantified 8OHdG in blinded longitudinal plasma samples taken 24 months apart from 160 TRACK-HD participants, as well as samples containing control plasma with added ("spiked") 8OHdG. One laboratory used a liquid chromatography-electrochemical array (LCECA) assay, and the other used liquid chromatography-mass spectrometry (LCMS).

RESULTS:

The LCMS assay was more accurate than the LCECA assay for measurements of "spiked" 8OHdG levels in plasma. Neither assay demonstrated cross-sectional differences in plasma 8OHdG among controls, premanifest HD, and early symptomatic HD. Similarly, neither assay showed longitudinal changes in any disease group over 24 months.

CONCLUSIONS:

Plasma concentration of 8OHdG is not a biomarker of disease state or progression in HD. We recommend that future putative biomarker studies use blinded sample analysis, standard curves, independent analytical methods, and strict quality control of sample collection and storage.

PMID:
23616162
PMCID:
PMC3716347
DOI:
10.1212/WNL.0b013e318293e1a1
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center